A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

ClinicalTrials.gov ID: NCT07266441

Public ClinicalTrials.gov record NCT07266441. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 9, 2026, 10:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Open-label Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refractory' if does not respond to treatment) who have received at least 3 prior lines of therapy.

Study identification

NCT ID: NCT07266441
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Janssen Research & Development, LLC; Industry
Enrollment: 157 participants

Conditions and interventions

Conditions

Multiple Myeloma

Interventions

JNJ-79635322 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 7, 2026
Primary completion: Jun 13, 2027
Completion: Dec 11, 2028
Last update posted: Aug 27, 2026

2026 – 2028

United States locations

U.S. sites: 30
U.S. states: 19
U.S. cities: 27

Facility	City	State	ZIP	Site status
O Neal Comprehensive Cancer Center at UAB	Birmingham	Alabama	35294	Active, not recruiting
Banner MD Anderson Cancer Center	Gilbert	Arizona	85234	Active, not recruiting
City of Hope	Duarte	California	91010	Active, not recruiting
City of Hope Orange County Lennar Foundation Cancer Center	Irvine	California	92618	Active, not recruiting
Cancer and Blood Specialty Clinic	Los Alamitos	California	90720	Active, not recruiting
University of California San Francisco	San Francisco	California	94143	Active, not recruiting
Rocky Mountain Cancer Centers	Aurora	Colorado	80012	Recruiting
Colorado Blood Cancer Institute	Denver	Colorado	80218	Active, not recruiting
Cancer Specialists of North Florida	Jacksonville	Florida	32256	Active, not recruiting
Emory University	Atlanta	Georgia	30322	Active, not recruiting
Northside Hospital Cancer Institute	Atlanta	Georgia	30342	Recruiting
Cancer Care Specialists of Central Illinois	O'Fallon	Illinois	62269	Recruiting
University of Iowa	Iowa City	Iowa	52242	Active, not recruiting
Mission Cancer Blood	Waukee	Iowa	50263	Recruiting
Massachusetts General Hospital	Boston	Massachusetts	02114	Active, not recruiting
Rutgers Cancer Institute	New Brunswick	New Jersey	08901	Active, not recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Active, not recruiting
Levine Cancer Institute	Charlotte	North Carolina	28204	Active, not recruiting
Cleveland Clinic Foundtation	Cleveland	Ohio	44195	Active, not recruiting
Oncology Associates of Oregon PC Willamette Valley Cancer Institute	Eugene	Oregon	97401	Recruiting
University of Pennsylvania	Philadelphia	Pennsylvania	19104	Active, not recruiting
SCRI Oncology Partners	Nashville	Tennessee	37203	Active, not recruiting
Tennessee Oncology, PLLC	Nashville	Tennessee	37203	Recruiting
Texas Oncology	Austin	Texas	78705	Active, not recruiting
MD Anderson Cancer Center	Houston	Texas	77030	Active, not recruiting
Oncology Consultants Texas	Houston	Texas	77030	Active, not recruiting
Texas Oncology - Northeast	Tyler	Texas	75702	Active, not recruiting
Virginia Cancer Specialists	Fairfax	Virginia	22031	Recruiting
Virginia Oncology Associates	Norfolk	Virginia	23502	Recruiting
NorthWest Medical Specialties, PLLC	Tacoma	Washington	98405	Active, not recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07266441, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 27, 2026 · Synced Sep 9, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07266441 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →